zvsromke

Property	Value
?:abstract	Background and study aims: The coronavirus disease 2019 (COVID-19) is a pandemic infection spreading worldwide at an unprecedented rate Our aim was to assess the frequency of gastrointestinal (GI) involvement in COVID-19 Patients and methods: We performed a systematic review and meta-analysis of all studies reporting clinical data about COVID-19 patients, published until 25th March 2020 The primary endpoint was the pooled prevalence of COVID-19 patients complaining of GI symptoms Secondary endpoints were the pooled prevalence of cases with COVID-19 positive stool samples, and of asymptomatic COVID-19 patients We used random-effects model for meta-analysis Results: Thirty-three studies were included in the meta-analysis Out of 4434 COVID-19 patients, the pooled prevalence of GI manifestations was 11 51% (95% CI : 8 16 to 15 35) The most frequent GI symptom was diarrhea (7 78% of cases ;95% CI : 5 05 to 11 04), followed by nausea/vomiting (3 57% ;95% CI : 1 87 to 5 80), poor appetite (2 39% ;95%CI : 0 55 ;5 46) and abdominal pain (0 78% ;95% CI : 0 26 to 1 57) Positivity for COVID-19 in stool samples was observed in 41 50% (95% CI : 17 70 to 67 65) of cases 11 85% (95% CI : 3 53 to 24 17) of COVID-19 patients remained asymptomatic Conclusions: The present meta-analysis shows that a significant proportion of COVID-19 patients suffer from GI manifestations, as well as COVID-19 positivity in stool samples Asymptomatic patients need to be considered a further potential route of viral transmission © Acta Gastro-Enterologica Belgica Background and study aims: The coronavirus disease 2019 (COVID-19) is a pandemic infection spreading worldwide at an unprecedented rate. Our aim was to assess the frequency of gastrointestinal (GI) involvement in COVID-19. Patients and methods: We performed a systematic review and meta-analysis of all studies reporting clinical data about COVID-19 patients, published until 25th March 2020. The primary endpoint was the pooled prevalence of COVID-19 patients complaining of GI symptoms. Secondary endpoints were the pooled prevalence of cases with COVID-19 positive stool samples, and of asymptomatic COVID-19 patients. We used random-effects model for meta-analysis. Results: Thirty-three studies were included in the meta-analysis. Out of 4434 COVID-19 patients, the pooled prevalence of GI manifestations was 11.51% (95% CI : 8.16 to 15.35). The most frequent GI symptom was diarrhea (7.78% of cases ; 95% CI : 5.05 to 11.04), followed by nausea/vomiting (3.57% ; 95% CI : 1.87 to 5.80), poor appetite (2.39% ; 95%CI : 0.55 ; 5.46) and abdominal pain (0.78% ; 95% CI : 0.26 to 1.57). Positivity for COVID-19 in stool samples was observed in 41.50% (95% CI : 17.70 to 67.65) of cases. 11.85% (95% CI : 3.53 to 24.17) of COVID-19 patients remained asymptomatic. Conclusions: The present meta-analysis shows that a significant proportion of COVID-19 patients suffer from GI manifestations, as well as COVID-19 positivity in stool samples. Asymptomatic patients need to be considered a further potential route of viral transmission.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/zvsromke_hasAnnotation_C0000737> <https://research.tib.eu/covid-19/entity/zvsromke_hasAnnotation_C0011991> <https://research.tib.eu/covid-19/entity/zvsromke_hasAnnotation_C0027498> <https://research.tib.eu/covid-19/entity/zvsromke_hasAnnotation_C0232462> <https://research.tib.eu/covid-19/entity/zvsromke_hasAnnotation_C0426576>
?:creator	<https://research.tib.eu/covid-19/entity/Merola%2C_E%3B_Armelao%2C_F%3B_de_Pretis%2C_G> <https://research.tib.eu/covid-19/entity/Merola%2C_E.%3B_Armelao%2C_F.%3B_de_Pretis%2C_G.>
?:journal	Acta_Gastroenterol_Belg Acta_gastro-enterologica_Belgica
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/zvsromke_HAS_C0426576_ASSOCIATED_WITH_C5203670> <https://research.tib.eu/covid-19/entity/zvsromke_HAS_C2744535_AFFECTS_C5203670>
?:source	WHO
?:title	Prevalence of gastrointestinal symptoms in coronavirus disease 2019: a meta-analysis
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#1012039 #976781
?:year	2020

Property

Value

?:abstract

Background and study aims: The coronavirus disease 2019 (COVID-19) is a pandemic infection spreading worldwide at an unprecedented rate Our aim was to assess the frequency of gastrointestinal (GI) involvement in COVID-19 Patients and methods: We performed a systematic review and meta-analysis of all studies reporting clinical data about COVID-19 patients, published until 25th March 2020 The primary endpoint was the pooled prevalence of COVID-19 patients complaining of GI symptoms Secondary endpoints were the pooled prevalence of cases with COVID-19 positive stool samples, and of asymptomatic COVID-19 patients We used random-effects model for meta-analysis Results: Thirty-three studies were included in the meta-analysis Out of 4434 COVID-19 patients, the pooled prevalence of GI manifestations was 11 51% (95% CI : 8 16 to 15 35) The most frequent GI symptom was diarrhea (7 78% of cases ;95% CI : 5 05 to 11 04), followed by nausea/vomiting (3 57% ;95% CI : 1 87 to 5 80), poor appetite (2 39% ;95%CI : 0 55 ;5 46) and abdominal pain (0 78% ;95% CI : 0 26 to 1 57) Positivity for COVID-19 in stool samples was observed in 41 50% (95% CI : 17 70 to 67 65) of cases 11 85% (95% CI : 3 53 to 24 17) of COVID-19 patients remained asymptomatic Conclusions: The present meta-analysis shows that a significant proportion of COVID-19 patients suffer from GI manifestations, as well as COVID-19 positivity in stool samples Asymptomatic patients need to be considered a further potential route of viral transmission © Acta Gastro-Enterologica Belgica
Background and study aims: The coronavirus disease 2019 (COVID-19) is a pandemic infection spreading worldwide at an unprecedented rate. Our aim was to assess the frequency of gastrointestinal (GI) involvement in COVID-19. Patients and methods: We performed a systematic review and meta-analysis of all studies reporting clinical data about COVID-19 patients, published until 25th March 2020. The primary endpoint was the pooled prevalence of COVID-19 patients complaining of GI symptoms. Secondary endpoints were the pooled prevalence of cases with COVID-19 positive stool samples, and of asymptomatic COVID-19 patients. We used random-effects model for meta-analysis. Results: Thirty-three studies were included in the meta-analysis. Out of 4434 COVID-19 patients, the pooled prevalence of GI manifestations was 11.51% (95% CI : 8.16 to 15.35). The most frequent GI symptom was diarrhea (7.78% of cases ; 95% CI : 5.05 to 11.04), followed by nausea/vomiting (3.57% ; 95% CI : 1.87 to 5.80), poor appetite (2.39% ; 95%CI : 0.55 ; 5.46) and abdominal pain (0.78% ; 95% CI : 0.26 to 1.57). Positivity for COVID-19 in stool samples was observed in 41.50% (95% CI : 17.70 to 67.65) of cases. 11.85% (95% CI : 3.53 to 24.17) of COVID-19 patients remained asymptomatic. Conclusions: The present meta-analysis shows that a significant proportion of COVID-19 patients suffer from GI manifestations, as well as COVID-19 positivity in stool samples. Asymptomatic patients need to be considered a further potential route of viral transmission.

is ?:annotates of